EpiAxis Therapeutics Announces Positive Clinical Trial Data for its New Drug Program to Inhibit Metastatic Breast Cancer
EpiAxis Therapeutics has announced a pioneering clinical study, showing that an epigenetic inhibitor combined with chemotherapy can treat metastatic cancer. SYDNEY, AUSTRALIA, June 9, 2022 /EINPresswire.com/ -- EpiAxis Therapeutics has announced the …